losartan has been researched along with Diabetic Nephropathies in 275 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 10.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 9.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| " Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced." | 9.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 9.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients." | 9.14 | Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 9.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 9.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 9.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 9.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 9.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 9.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 8.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 7.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| " With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined." | 7.73 | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 6.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 6.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| " The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study provided the opportunity to estimate costs associated with ESRD by baseline albuminuria from a United States perspective." | 6.21 | Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Carides, GW; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2004) |
| "As angiotensin II type 1 receptor blockers (ARBs) may have different antiproteinuric effects in diabetic kidney disease (DKD), we ascertained the albuminuria-reducing effect of fimasartan and losartan in patients with DKD." | 5.51 | The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial. ( Han, BG; Han, SY; Hong, SJ; Hur, KY; Kang, YS; Kim, DK; Kim, S; Kim, YJ; Lee, JP; Lee, S; Na, KR; Park, J; Park, S; Shin, S; Won, JC; Yoo, TH, 2022) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 5.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| " Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced." | 5.20 | Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. ( Fu, SK; Gu, HF; Hu, C; Jin, HM; Liu, XL; Pan, LH; Pan, Y; Qiao, QY; Zhou, DC, 2015) |
| " Telmisartan, one of the currently available angiotensin II type 1 receptor blockers (ARBs), has been shown to exert a more powerful proteinuria (albuminuria) reduction in patients with DN, but whether the prominent renoprotective effect of telmisartan is mediated through enhancing antioxidant defense capacity and reducing oxidative stress has not been fully elucidated." | 5.15 | Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. ( Fujishima, H; Fujita, H; Komatsu, K; Morii, T; Narita, T; Sakamoto, T; Takahashi, T; Yamada, Y, 2011) |
| "We conducted a multicenter, controlled trial involving 285 normotensive patients with type 1 diabetes and normoalbuminuria and who were randomly assigned to receive losartan (100 mg daily), enalapril (20 mg daily), or placebo and followed for 5 years." | 5.14 | Renal and retinal effects of enalapril and losartan in type 1 diabetes. ( Donnelly, S; Drummond, K; Gardiner, R; Goodyer, P; Gubler, MC; Klein, R; Mauer, M; Sinaiko, A; Strand, T; Suissa, S; Zinman, B, 2009) |
| " A total of 30 patients with type II diabetes, along with hypertension and overt nephropathy, were enrolled in this randomized, two-period, crossover trial of 12 weeks of treatment with losartan (50 mg daily) and telmisartan (40 mg daily)." | 5.14 | Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. ( Azuma, K; Dejima, T; Kanaoka, T; Maeda, A; Masuda, S; Ohsawa, M; Tamura, K; Umemura, S; Wakui, H; Yanagi, M, 2009) |
| " We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily)." | 5.14 | Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. ( Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL, 2009) |
| "A prospective, open label, parallel group and randomized study was conducted to see the effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients." | 5.14 | Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. ( Hoque, R; Iqbal, M; Rahman, MS, 2009) |
| "Aliskiren added to losartan reduced albuminuria and renal dysfunction and was well tolerated, except for hyperkalemia (stage 3), independent of baseline CKD stage in patients with type 2 diabetes, hypertension, and nephropathy." | 5.14 | Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F; Rossing, P, 2010) |
| " We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy." | 5.13 | Aliskiren combined with losartan in type 2 diabetes and nephropathy. ( Hollenberg, NK; Lewis, EJ; Lewis, JB; Parving, HH; Persson, F, 2008) |
| " We investigated whether this polymorphism is predictive of reductions in blood pressure and albuminuria and preservation of glomerular filtration rate (GFR) during short-term and long-term treatment with losartan in 57 hypertensive type-1 diabetic patients with diabetic nephropathy." | 5.12 | Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. ( Andersen, S; Lajer, M; Parving, HH; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006) |
| "In this study we evaluated the effect of a dual blockade with enalapril and losartan on the reduction of overt macroproteinuria and its potential mechanism(s) in hypertensive patients with type 2 diabetes." | 5.12 | Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. ( Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M, 2006) |
| "In addition to reducing urinary protein excretion, losartan at 100 mg daily increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetic nephropathy." | 5.12 | Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. ( Jin, HM; Pan, Y, 2007) |
| " Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 5.12 | Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z, 2007) |
| "Forty-one ARB- and ACE inhibitor-naive T2DM subjects with albuminuria (>30 mg/g creatinine) were given either 50 mg of losartan (ARB) or 20 mg of quinapril (ACE inhibitor) (50% maximum dose) for 4 weeks, with a 4-week wash-out period in-between interventions in a crossover fashion." | 5.12 | Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. ( Chua, CL; Goh, SK; Heng, BL; Koh, AF; Lim, SC; Subramaniam, T; Sum, CF, 2007) |
| "We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria." | 5.11 | Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, S; Zhang, Z, 2004) |
| "This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects." | 5.11 | Losartan and end-organ protection--lessons from the RENAAL study. ( Brenner, BM; Dickson, TZ; Kowey, PR; Shahinfar, S; Zhang, Z, 2005) |
| "We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy." | 5.11 | Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S, 2005) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "Recently, the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study demonstrated the benefit of losartan in reducing renal outcomes in patients with type 2 diabetes and proteinuria." | 5.10 | Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study. ( Ahmed, T; Brenner, BM; Dickson, TZ; Ramjit, D; Shahinfar, S; Smith, RD; Zhang, Z, 2002) |
| "We studied the efficacy of losartan (50 mg once daily for 12 weeks) on albuminuria, peripheral and autonomic neuropathy in 25 normotensive microalbuminuric type 2 diabetics who were asymptomatic for neuropathy." | 5.10 | Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics. ( Agarwal, SK; Anuradha, S; Babbar, R; Kubba, S; Prakash, A; Puri, V, 2003) |
| "5 mg of hydrochlorothiazide, in 90 type 2 diabetic patients with microalbuminuria and blood pressure > 130/85 mmHg, receiving losartan 50 mg as initial treatment during 4 weeks." | 5.10 | Losartan titration versus diuretic combination in type 2 diabetic patients. ( de Pablos-Velasco, PL; Esmatjes, JE; Fernandez-Vega, F; Lopez de la Torre, ML; Pazos Toral, F; Pozuelo, A; Ruilope, LM, 2002) |
| "The objectives of this study were to compare the effects of the angiotensin II receptor blocker, losartan, to those of the angiotensin-converting enzyme inhibitor, enalapril, on albuminuria and renal function in relationship to clinic and ambulatory blood pressure (ABP) in hypertensive type 2 diabetic subjects with early nephropathy." | 5.09 | Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. ( Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000) |
| "There is an incremental clinical benefit of irbesartan over losartan in the treatment of hypertension and diabetic nephropathy which can be substantiated by corresponding preclinical study evidence." | 4.86 | Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. ( Bramlage, P; Schindler, C, 2010) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 4.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| " THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add-on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis." | 4.31 | Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. ( Khazaali, M; Khazaeli, M; Lau, WL; Nunes, ACF; Prudente, J; Singh, B; Vaziri, ND; Zhao, Y, 2023) |
| "This study used data from three randomized intervention trials (Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy, Selective Vitamin D Receptor Activation for Albuminuria Lowering, and Residual Albuminuria Lowering with Endothelin Antagonist Atrasentan) including patients with type 2 diabetes and macroalbuminuria." | 3.81 | Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. ( Andress, DL; Bijlsma, MJ; de Zeeuw, D; Heerspink, HJ; Kröpelin, TF; Parving, HH; Persson, F, 2015) |
| "The aim of this study was to evaluate the effect of compound 21 (C21), a selective AT2 receptor agonist, on diabetic nephropathy and the potential additive effect of C21, when associated with losartan treatment, on the development of albuminuria and renal fibrosis in Zucker diabetic fatty (ZDF) rats." | 3.80 | Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. ( Bombardi, C; Carletti, R; Castoldi, G; Dahlöf, B; di Gioia, CR; Maestroni, S; Steckelings, UM; Stella, A; Unger, T; Zerbini, G, 2014) |
| "Losartan is an orally active, selective, nonpeptide, angiotensin II AT(1) receptor antagonist." | 3.80 | Losartan in diabetic nephropathy. ( Carswell, CI; Goa, KL, 2003) |
| " Patients were administered either losartan or placebo, each in addition to conventional antihypertensive therapy, with dosage adjustments as necessary to achieve a target blood pressure of less than 140/less than 90 mm Hg." | 3.80 | Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. ( Keane, WF; Lyle, PA, 2003) |
| "We investigated the effects of dual renin-angiotensin system (RAS) blockade on angiotensin-converting enzyme-2 (Ace2) expression, hypertension, and renal proximal tubular cell (RPTC) apoptosis in type 1 diabetic Akita angiotensinogen (Agt)-transgenic (Tg) mice that specifically overexpress Agt in their RPTCs." | 3.78 | Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. ( Chan, JS; Chenier, I; Filep, JG; Godin, N; Ingelfinger, JR; Liu, F; Lo, CS; Maachi, H; Shi, Y; Zhang, SL, 2012) |
| "Aliskiren significantly attenuated albuminuria and glomerular mesangial matrix expansion in db/db mice, which was associated with the improvement of the increased glomerular transforming growth factor-beta and type IV collagen expressions, the increased macrophage infiltration, and the decreased glomerular nephrin expression of db/db mice." | 3.76 | Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E, 2010) |
| "After 12 weeks of the treatment with losartan, albuminuria was reduced from baseline by 9% [95% confidence interval (CI): 1-17, p = 0." | 3.76 | Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. ( Ajdinović, B; Andelković, Z; Dragović, T; Hrvacević, R; Ilić, V; Kocev, N; Magić, Z, 2010) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| " We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury." | 3.74 | Overexpression of angiotensinogen increases tubular apoptosis in diabetes. ( Brezniceanu, ML; Chan, JS; Chénier, I; Filep, JG; Ingelfinger, JR; Liu, F; Sachetelli, S; Wei, CC; Zhang, SL, 2008) |
| " With the use of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study database as an example, the influence of baseline proteinuria on the primary composite endpoint, ESRD, and ESRD or death after adjusting for baseline proteinuria as a continuous covariate was examined." | 3.73 | Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. ( Brenner, BM; de Zeeuw, D; Dickson, TZ; Gleim, GW; Keane, WF; Mogensen, CE; Ramjit, D; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "We examined the effects of combined treatment with SMP-534 and losartan on urinary albumin and glomerular fibrosis in db/db mice." | 3.73 | Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2006) |
| "Losartan and captopril have comparable effects on reducing albuminuria in a diabetic rat model." | 3.70 | The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model. ( Ahiskali, R; Akalin, S; Budak, Y; Ekicioglu, G; Emerk, K; Ersöz, O; Kuçükkaya, B; Yavuz, DG, 1999) |
| " Angiotensin-converting enzyme (ACE) inhibitors appear to be the drugs of choice since they not only lower blood pressure but also reduce some important risk factors that may cause progressive loss of renal function, such as intraglomerular hypertension, angiotensin II (Ang II)-induced glomerular growth, proteinuria and hyperlipidemia." | 3.69 | Losartan in patients with renal insufficiency. ( de Jong, PE; de Zeeuw, D; Gansevoort, RT, 1995) |
| " Thus, we aim to evaluate whether losartan potassium combined with KLX is more effective than losartan potassium in DKD treatment and to provide validated evidence for the application of KLX in the treatment of DKD." | 2.94 | Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial. ( Bai, L; Li, F; Li, J; Qu, L; Wang, Q; Wei, F; Wei, J; Wu, R; Yan, W, 2020) |
| "Participants were American Indians with type 2 diabetes enrolled in a clinical trial of losartan versus placebo." | 2.90 | Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. ( Boustany-Kari, CM; Esplin, CA; Guarnieri, P; Harder, JL; Hill, J; Kretzler, M; Looker, HC; Mauer, M; Nair, V; Najafian, B; Nelson, RG; Saulnier, PJ, 2019) |
| " We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN)." | 2.82 | Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. ( Adams-Huet, B; Srivastava, A; Toto, RD; Vega, GL, 2016) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Proteinuric diabetic kidney disease frequently progresses to ESRD." | 2.80 | BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial. ( Emanuele, NV; Fried, LF; Guarino, P; Leehey, DJ; Palevsky, PM; Reilly, RF; Whaley-Connell, A; Zhang, JH, 2015) |
| "Treatment with losartan may preserve some features of kidney structure in American Indians with type 2 diabetes and microalbuminuria." | 2.78 | Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. ( Bennett, PH; Fufaa, G; Hanson, RL; Jones, LI; Knowler, WC; Lemley, KV; Lovato, T; Myers, BD; Nelson, RG; Weil, EJ; Yee, B, 2013) |
| "In patients with type 2 diabetes, by comparison, the mean percentage of podocyte detachment was significantly higher in macroalbuminuria (1." | 2.77 | Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. ( Blouch, K; Jones, LI; Lemley, KV; Lovato, T; Mason, CC; Myers, BD; Nelson, RG; Richardson, M; Weil, EJ; Yee, B, 2012) |
| "Losartan was an independent predictor for serum potassium ≥5." | 2.76 | Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Dobre, D; Grobbee, D; Heerspink, HJ; Miao, Y; Parving, HH; Shahinfar, S, 2011) |
| "Diabetic nephropathy is the most frequent cause of end stage renal disease (ESRD)." | 2.76 | Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA. ( Cammarota, S; Citarella, A; de Portu, S; Mantovani, LG; Menditto, E, 2011) |
| " The adverse effects included dry cough (seven [19." | 2.75 | Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. ( Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010) |
| "Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D)." | 2.75 | Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. ( Fujiwara, N; Koide, H; Nakamura, T; Sato, E; Sugaya, T; Ueda, Y, 2010) |
| "Insulin resistance was calculated using fasting glucose and insulin, expressed as HOMA-IR." | 2.74 | Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. ( Guo, LL; Jin, HM; Pan, Y, 2009) |
| "This study was performed to ascertain whether losartan combined with pioglitazone is superior to losartan alone in delaying the progression of chronic renal failure in patients with type 2 diabetic nephropathy." | 2.73 | Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. ( Jin, HM; Pan, Y, 2007) |
| "Losartan treatment reduced renal outcomes in proteinuric patients with type 2 diabetes in the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study." | 2.73 | ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Liu, N; Lunceford, J; Lyle, PA; Parving, HH; Remuzzi, G; Rossing, P; Shahinfar, S; Wong, PH, 2008) |
| "In patients with diabetic nephropathy, lowering blood pressure and reducing proteinuria by over 30% correlates with a slower progression to kidney failure." | 2.73 | Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. ( Bakris, G; Burgess, E; Davidai, G; Koval, S; Weir, M, 2008) |
| "Losartan has been shown to protect the diabetic kidney, at least partly independent of changes in blood pressure." | 2.72 | The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. ( Baggen, MG; Boersma, E; Bootsma, AH; Janssen, JA; Lamberts, SW; Zandbergen, AA, 2006) |
| "Diabetic retinopathy was determined by masked grading of 30 degrees color stereoscopic fundus photographs of 7 standard fields using the Early Treatment Diabetic Retinopathy Study severity scale." | 2.72 | The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study. ( Donnelly, SM; Gardiner, R; Goodyer, P; Klein, R; Kramer, MS; Mauer, M; Moss, SE; Sinaiko, AR; Strand, T; Suissa, S; Zinman, B, 2006) |
| " We tested for effect modification by age of the effect of losartan on the incidence of the predefined end points (doubling of serum creatinine, end-stage renal disease [ESRD], or death) and the risk of adverse events." | 2.72 | Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. ( Avorn, J; Brenner, BM; Cooper, ME; Shahinfar, S; Winkelmayer, WC; Zhang, Z, 2006) |
| "Levels of proteinuria were reduced with losartan compared with placebo, with an overall losartan treatment effect of 37." | 2.72 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. ( Chan, JC; Cooper, ME; Keane, WF; Kurokawa, K; Shahinfar, S; Zhang, Z, 2006) |
| "Treatment with losartan in patients with type 2 diabetes and nephropathy not only reduced the incidence of ESRD, but also resulted in substantial cost savings." | 2.71 | Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. ( Alexander, CM; Brenner, BM; Carides, GW; Cook, JR; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2003) |
| "The reduction in the number of ESRD days over 4 years in patients treated with losartan significantly decreased costs associated with ESRD by 7,438 euros per patient (CI 95%: 3,029 euros - 11,847 euros, p=0." | 2.71 | An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. ( Durand Zaleski, I; Gaugris, S; Hannedouche, T; Passa, P; Rodier, M; Souchet, T, 2003) |
| "In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, approximately 17% of patients were Asians." | 2.71 | Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. ( Brenner, BM; Chan, JC; Chua, CT; Cooper, ME; Dickson, TZ; Hille, D; Kurokawa, K; Lam, KS; Morad, Z; Shahinfar, S; So, WY; Wat, NM; Wong, KS; Zhang, Z, 2004) |
| "The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes." | 2.71 | Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. ( Burgess, ED; Carides, GW; Chabot, I; Gerth, WC; Marentette, MA, 2004) |
| "Using FAM to treat 31 patients with diabetic nephropathy and controlled by 23 patients treated with Losartan, the therapeutic course was 3 months for both groups, changes of clinical symptoms, blood glucose, lipid metabolism and urinary albumin were observed and compared." | 2.71 | [Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture]. ( Chen, YP; Wang, HY, 2004) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD)." | 2.71 | Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Keane, WF; Mohanram, A; Shahinfar, S; Toto, RD; Zhang, Z, 2004) |
| "Diabetic nephropathy with ESRD for type 2 diabetes mellitus (DM) now has to be recognized as a growing public health problem." | 2.71 | The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study. ( Keusch, GW; Sandoz, MS; Szucs, TD, 2004) |
| "In proteinuric individuals with type 2 diabetes, losartan therapy reduced ESRD and hospitalizations for heart failure and was well tolerated at all levels of renal function." | 2.71 | Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. ( Brenner, BM; Carides, GW; de Zeeuw, D; Dimitrov, BD; Hille, DA; Perna, A; Remuzzi, G; Ruggenenti, P; Shahinfar, S, 2004) |
| "Treatment with losartan in patients with type 2 diabetic nephropathy not only reduced the incidence of ESRD among Asian patients, but resulted in direct medical cost savings in countries or regions representing Asia." | 2.71 | Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. ( Burke, TA; Carides, GW; Chan, J; Choi, YJ; Han, DC; Hwang, SJ; Seng, WK; Teong, CC, 2005) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease." | 2.70 | [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. ( Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z, 2001) |
| "Losartan 100 mg was more effective than 50 mg in reducing albuminuria, 51% (95% CI; 40 to 61) versus 33% (23 to 42), respectively (P < 0." | 2.70 | Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? ( Andersen, S; Cambien, F; Deinum, J; Juhl, TR; Parving, HH; Rossing, P; Tarnow, L, 2002) |
| " However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness." | 2.46 | Comparing angiotensin II receptor blockers on benefits beyond blood pressure. ( Siragy, HM, 2010) |
| " There were no dose-response renal effects of losartan." | 2.45 | Inhibition of the renin-angiotensin system: is more better? ( Anderson, S; Komers, R, 2009) |
| "Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 microg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality." | 2.45 | Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. ( Bichu, P; Khan, A; Nistala, R; Sowers, JR; Whaley-Connell, A, 2009) |
| "Losartan is a competitive antagonist that causes a parallel rightward shift of the concentration-contractile response curve to angiotensin-II, while E 3174 is a noncompetitive "insurmountable" antagonist of angiotensin-II." | 2.43 | Clinical pharmacokinetics of losartan. ( Gehr, TW; Ghosh, S; Sica, DA, 2005) |
| "Losartan is a selective non-peptide angiotensin Type 1-receptor blocker (ARB) with unique uricosuric effect, not shared by other ARBs." | 2.43 | Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. ( Chiurchiu, C; Parvanova, A; Remuzzi, G; Ruggenenti, P, 2005) |
| "Diabetes (particularly type 2 diabetes) represents a global health problem of epidemic proportions." | 2.43 | Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. ( Burnier, M; Zanchi, A, 2006) |
| "The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study was conducted from 1996 to 2001." | 2.43 | Losartan: lessons learned from the RENAAL study. ( Brenner, BM; Keane, WF; Lyle, PA; Shahinfar, S; Zhang, Z, 2006) |
| "For patients with type 2 diabetes mellitus (T2DM) and hypertension, an AII receptor blocker (AIIRB) is recommended as the first drug that should be used." | 2.42 | Advances in the treatment of diabetic renal disease: focus on losartan. ( Rayner, B, 2004) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min." | 2.42 | Losartan in diabetic nephropathy. ( Perico, N; Remuzzi, G; Ruggenenti, P, 2004) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) studied the effect of the angiotensin receptor blocker (ARB) irbesartan on the reduction of BP, urinary protein excretion, and progression to DN." | 2.42 | Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. ( Hunsicker, LG, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "Treatment with crocin and losartan decreased these biochemical parameters and increased the expression of the BMP7 and FRMD3 genes." | 1.91 | Effect of crocin and losartan on biochemical parameters and genes expression of FRMD3 and BMP7 in diabetic rats. ( Farimani, AR; Mohammadi, Y; Salmani, F; Zangooei, M, 2023) |
| "In patients with diabetic kidney disease (DKD), the estimated glomerular filtration rate (eGFR) or creatinine clearance rate (Ccr) is always used as an index of decline in renal function." | 1.91 | Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions. ( Fukui, K; Inagaki, K; Maekawa, M; Miyajima, K; Ohta, T; Shinozaki, Y; Toyoda, K; Uno, K; Yoshiuchi, H, 2023) |
| " In addition, the nephrectomized db /db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II-receptor antagonist losartan." | 1.72 | Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease. ( Kitamoto, M; Konishi, N; Maekawa, M; Maekawa, T; Nakagawa, T; Ohta, T; Sasase, T; Takagi, K; Takeuchi, S; Toyoda, K; Yamada, T, 2022) |
| "Podocyte loss and proteinuria are both key features of human diabetic nephropathy (DN)." | 1.56 | Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. ( Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA, 2020) |
| "Treatment with losartan reduced urinary protein excretion and blood lipids (triglyceride and cholesterol) dose-dependently in both studies." | 1.48 | Losartan improves renal function and pathology in obese ZSF-1 rats. ( Donnelly-Roberts, D; Gopalakrishnan, M; Leys, L; McGaraughty, S; Namovic, M; Nikkel, A; Su, Z; Widomski, D, 2018) |
| "Type 1 diabetes was induced by a single 60 mg/kg intraperitoneal injection of streptozotocin in Sprague-Dawley rats." | 1.48 | A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats. ( Bae, YS; Cha, DR; Dorotea, D; Ha, H; Kwon, G; Lee, JH; Lee, SJ; Moon, SH; Saunders, E, 2018) |
| " In addition, the renoprotection of DPP4i combined with ARBs was independent of glycemic control." | 1.48 | Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy. ( An, Y; Ge, YC; Jiang, S; Liu, J; Qiu, DD; Shi, JS; Zhou, ML, 2018) |
| " Moreover, levocetirizine attenuated the elevated renal levels of TNF-α and TGF-β1, ameliorated renal oxidative stress and restored NO bioavailability in diabetic kidney." | 1.43 | Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats. ( Anbar, HS; Gameil, NM; Shehatou, GS; Suddek, GM, 2016) |
| "BACKGROUND Diabetic nephropathy (DN) is the most lethal diabetic microvascular complication; it is a major cause of renal failure, and an increasingly globally prominent healthcare problem." | 1.43 | Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice. ( Fan, Q; Jiang, Y; Liu, X; Wang, L; Yang, G; Zhang, C; Zhu, X, 2016) |
| "Losartan attenuated key parameters of diabetic nephropathy and gene expression, and reversed some but not all the epigenetic changes in db/db mice." | 1.40 | Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. ( Alpers, CE; Bomsztyk, K; Lanting, L; Mar, D; Natarajan, R; Reddy, MA; Sumanth, P; Wang, M; Yuan, H, 2014) |
| "Bilirubin was inversely associated with the renal end point in RENAAL independent of age, sex, race, BMI, smoking, total cholesterol, diastolic blood pressure, HbA1c, treatment, estimated glomerular filtration rate, albumin-to-creatinine ratio, and AST." | 1.40 | Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. ( Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ, 2014) |
| "A non-obese type 2 diabetes model, the spontaneously diabetic Torii (SDT) rat, is of increasing preclinical interest because of its pathophysiological similarities to human type 2 diabetic complications including diabetic nephropathy." | 1.40 | Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan. ( Fujitaka, K; Fukunari, A; Hirohashi, Y; Iguchi, T; Kakimoto, T; Kato, T; Kawai, M; Nishio, M; Okada, K; Relator, R; Utsumi, H, 2014) |
| "Diabetic nephropathy is a major cause of end-stage kidney disease, and overactivity of the endocannabinoid/cannabinoid 1 receptor (CB1R) system contributes to diabetes and its complications." | 1.40 | Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. ( Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Ju, C; Kunos, G; Liu, J; Liu, Z; Pacher, P; Rosenberg, AZ; Szanda, G; Tam, J, 2014) |
| "Enalapril was found to be more reno-protective compared to losartan." | 1.40 | COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL. ( Mugendi, GA; Mwangi, M; Ndwiga, S; Nyamu, DG; Nyamweya, NN; Okalebo, FA, 2014) |
| "The AKT-mTOR pathway is activated in diabetic nephropathy." | 1.39 | Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy. ( Daphnis, E; Ganotakis, E; Giannakakis, K; Katsarou, T; Mavroeidi, V; Papavasiliou, S; Perakis, K; Petrakis, I; Stratigis, S; Stylianou, K; Vardaki, E, 2013) |
| "Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period." | 1.37 | Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. ( Andersen, S; Hess, G; Nielsen, SE; Parving, HH; Rossing, P; Zdunek, D, 2011) |
| "To test this strategy in a model of type 2 diabetes, we treated 2-month-old diabetic Lprdb/db mice with losartan, paricalcitol, or a combination of losartan and paricalcitol for 3 months." | 1.36 | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. ( Chang, A; Deb, DK; Kong, J; Li, YC; Ning, G; Shi, H; Sun, T; Wong, KE; Zhang, Y; Zhang, Z, 2010) |
| "ARB improved the NOS uncoupling in diabetic nephropathy by increasing BH4 bioavailability." | 1.35 | Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. ( Arakawa, S; Fujimoto, S; Haruna, Y; Horike, H; Kashihara, N; Namikoshi, T; Sasaki, T; Satoh, M; Yada, T, 2008) |
| "Losartan could suppress the expression of COX2 and TGF-beta1 in the kidney of DN rats and attenuate the renal lesions caused by DN." | 1.35 | Effect of losartan on cyclooxygenase-2 expression in normal human mesangial cells and kidneys of rats with diabetic nephropathy. ( Liu, ZC; Peng, WS; Yang, JH; Yuichiro, Y; Zhou, QL, 2008) |
| "The rat model of diabetic nephropathy was established by streptozotozin(STZ) injection, and the rats were randomly divided into 3 groups: (a normal group, a model group and a losartan group)." | 1.35 | [The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy]. ( Liu, JS; Ning, WB; Tao, LJ; Wang, L; Xu, JY, 2008) |
| " There was no dose-response effect of losartan." | 1.35 | Regression of glomerular injury by losartan in experimental diabetic nephropathy. ( Fujihara, CK; Machado, FG; Malheiros, DM; Silva, LF; Teles, F; Ventura, BH; Zatz, R, 2009) |
| "Losartan treatment resulted in improvement of myocardial function and suppressed cardiac and renal fibrosis compared with the diabetic group." | 1.35 | Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats. ( Aizawa, Y; Arozal, W; Kodama, M; Ma, M; Suzuki, K; Tachikawa, H; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K, 2009) |
| "Renin angiotensin system (RAS) worsens diabetic nephropathy (DN) by increasing oxidative stress." | 1.35 | Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats. ( Boada, J; Buleon, M; Girolami, JP; Gonzalo, H; Jové, M; Linz, W; Pamplona, R; Portero-Otín, M; Schäfer, S; Tack, I, 2008) |
| "Diabetic nephropathy is the main cause of end-stage renal disease." | 1.34 | Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. ( Hume, WE; Kitoh, M; Nagamine, J; Nagata, R; Nakagawa, T; Ono-Kishino, M; Sugaru, E; Taiji, M; Tokunaga, T, 2007) |
| "Losartan was well tolerated and demonstrated significant anti-proteinuric effects in patients with T2DM with early nephropathy independent of hypertension, warranting further long-term large-scale studies to prove its usefulness as preventive therapy for diabetic nephropathy." | 1.34 | Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. ( Agha, A; Anwar, E; Bashir, K, 2007) |
| "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide." | 1.33 | Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. ( Brenner, BM; Chan, J; de Zeeuw, D; Kurokawa, K; Lash, JP; Ramjit, D; Remuzzi, G; Ribeiro, AB; Shahinfar, S; Zhang, Z, 2006) |
| "Treatment with losartan plus CT in patients with type 2 diabetes and nephropathy reduced the within-trial incidence of ESRD and is projected to result in lifetime reductions in ESRD and associated costs, and increased survival, versus placebo." | 1.33 | The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. ( Alexander, CM; Brenner, BM; Carides, GW; Dasbach, EJ; Gerth, WC; Herman, WH; Keane, WF; Shahinfar, S, 2006) |
| "In Losartan treatment group, all of MPA, 24 hours urine protein count, kidney weight/body weight and Ccr decreased, compared with those of model group; ET-1 in blood and urine decreased too, especially the decreasing of ET-1 in urine (P < 0." | 1.32 | [Protective effect of angiotensin II receptor blockage on rats with experimental diabetes nephropathy in early stage]. ( Fan, J; Liu, X; Mi, X; Xu, G; Yang, L, 2003) |
| "Losartan treatment significantly prevented all these changes except STZ-induced hypoinsulinemia." | 1.32 | Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction. ( Goyal, RK; Murali, B; Umrani, DN, 2003) |
| "Fifty-seven patients with diabetic nephropathy were divided equally into group A with treatment with losartan (50 mg) and fosinopril (10 mg) daily, group B with daily losartan treatment (50-100 mg), and group C with fosinopril treatment at the daily dose of 10-20 mg." | 1.32 | [Combination therapy with losartan and fosinopril for early diabetic nephropathy]. ( Huang, YH; Shen, W; Wang, HT; Wang, Y; Zhang, H; Zhu, QZ, 2003) |
| "Apoptosis occurs in diabetic nephropathy, involving tubular and interstitial cells, an effect reversed by insulin therapy." | 1.32 | Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. ( Burns, KD; Kumar, D; Robertson, S; Zimpelmann, J, 2004) |
| "Losartan was administered at 3 and 10 mg/kg/day and enalapril at 3 mg/kg/day for 14 weeks in the drinking water." | 1.32 | Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice. ( Kemi, M; Matsumoto, H; Nishikibe, M; Ohta, H; Sasaki, M; Taguchi, K; Uehara, S, 2004) |
| "Losartan can prevent the development of diabetic nephropathy and inhibit MT3-MMP and the TIMP2 mRNA expressions in diabetic rat kidneys." | 1.32 | [Effects of losartan on MT3-MMP and TIMP2 mRNA expressions in diabetic rat kidney]. ( Huang, HH; Li, JG; Wan, X, 2004) |
| "Treatment with losartan 100 and 150 mg lowered GFR by 4 ml/min/1." | 1.31 | Optimal dose of losartan for renoprotection in diabetic nephropathy. ( Andersen, S; Deinum, J; Juhl, TR; Parving, HH; Rossing, P, 2002) |
| "Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union." | 1.31 | Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. ( Brenner, B; Carides, GW; Gerth, WC; Hannedouche, T; Martinez-Castelao, A; Remuzzi, G; Shahinfar, S; Viberti, G, 2002) |
| "Reduction of proteinuria is a prerequisite for successful long-term renoprotection." | 1.31 | Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. ( Andersen, S; Bos, H; De Jong, PE; De Zeeuw, D; Navis, G; Parving, HH; Rossing, P, 2000) |
| "Treatment with losartan significantly prevented the raise in cholesterol, creatinine, urea and blood urea nitrogen levels." | 1.31 | Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. ( Goyal, RK; Murali, B, 2001) |
| "Patients with Type 2 diabetes and nephropathy should receive either an AT(1) antagonist or the angiotensin converting enzyme inhibitor ramipril to ensure renoprotection." | 1.31 | Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy. ( Doggrell, SA, 2002) |
| "We conclude that in patients with diabetic nephropathy addition of AT1a therapy to ACEi therapy attenuates AngII effects better than ACEi therapy alone." | 1.30 | Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. ( Cosio, FG; Falkenhain, ME; Hebert, LA; Nahman, NS; O'Dorisio, TM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (2.18) | 18.2507 |
| 2000's | 160 (58.18) | 29.6817 |
| 2010's | 99 (36.00) | 24.3611 |
| 2020's | 10 (3.64) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Peng, Z | 1 |
| Lu, M | 1 |
| Xiong, X | 1 |
| Chen, Z | 1 |
| Li, Q | 1 |
| Cheng, Z | 1 |
| Jiang, D | 1 |
| Tao, L | 1 |
| Hu, G | 1 |
| Maekawa, M | 2 |
| Maekawa, T | 1 |
| Sasase, T | 1 |
| Takagi, K | 1 |
| Takeuchi, S | 1 |
| Kitamoto, M | 1 |
| Nakagawa, T | 4 |
| Toyoda, K | 2 |
| Konishi, N | 1 |
| Ohta, T | 2 |
| Yamada, T | 1 |
| Eita, MAH | 1 |
| Ashour, RH | 1 |
| El-Khawaga, OY | 1 |
| Dorotea, D | 2 |
| Jiang, S | 2 |
| Pak, ES | 1 |
| Son, JB | 1 |
| Choi, HG | 1 |
| Ahn, SM | 1 |
| Ha, H | 2 |
| Yoo, TH | 1 |
| Hong, SJ | 1 |
| Kim, S | 1 |
| Shin, S | 1 |
| Kim, DK | 1 |
| Lee, JP | 1 |
| Han, SY | 1 |
| Lee, S | 1 |
| Won, JC | 1 |
| Kang, YS | 1 |
| Park, J | 1 |
| Han, BG | 1 |
| Na, KR | 1 |
| Hur, KY | 1 |
| Kim, YJ | 1 |
| Park, S | 1 |
| Mohammadi, Y | 1 |
| Zangooei, M | 1 |
| Salmani, F | 1 |
| Farimani, AR | 1 |
| Khazaeli, M | 1 |
| Nunes, ACF | 1 |
| Zhao, Y | 1 |
| Khazaali, M | 1 |
| Prudente, J | 1 |
| Vaziri, ND | 2 |
| Singh, B | 1 |
| Lau, WL | 1 |
| Shinozaki, Y | 1 |
| Fukui, K | 1 |
| Yoshiuchi, H | 1 |
| Inagaki, K | 1 |
| Uno, K | 1 |
| Miyajima, K | 1 |
| Huang, WJ | 1 |
| Meng, X | 1 |
| Yang, F | 1 |
| Bao, Q | 1 |
| Zhang, MZ | 1 |
| Yang, YN | 1 |
| Ni, Q | 1 |
| Lian, FM | 1 |
| Tong, XL | 1 |
| Hudkins, KL | 1 |
| Wietecha, TA | 1 |
| Steegh, F | 1 |
| Alpers, CE | 2 |
| Wu, R | 1 |
| Wei, F | 1 |
| Qu, L | 1 |
| Bai, L | 1 |
| Li, J | 2 |
| Li, F | 1 |
| Yan, W | 1 |
| Wang, Q | 1 |
| Wei, J | 1 |
| Gao, H | 1 |
| Du, WY | 1 |
| Lin, J | 1 |
| Han, SL | 1 |
| Zhang, YJ | 1 |
| Sun, XF | 1 |
| Eltablawy, N | 1 |
| Ashour, H | 1 |
| Rashed, LA | 1 |
| Hamza, WM | 1 |
| Su, Z | 1 |
| Widomski, D | 1 |
| Nikkel, A | 1 |
| Leys, L | 1 |
| Namovic, M | 1 |
| Donnelly-Roberts, D | 1 |
| Gopalakrishnan, M | 1 |
| McGaraughty, S | 1 |
| Tahara, A | 1 |
| Takasu, T | 1 |
| Rabizadeh, S | 1 |
| Dehghani Firouzabadi, F | 1 |
| Noshad, S | 1 |
| Esteghamati, S | 1 |
| Afarideh, M | 1 |
| Ghajar, A | 1 |
| Ganji, M | 1 |
| Saadat, M | 1 |
| Heidari, B | 1 |
| Najafi, MT | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Pitt, B | 1 |
| Bakris, GL | 2 |
| Weir, MR | 4 |
| Freeman, MW | 1 |
| Lainscak, M | 1 |
| Mayo, MR | 1 |
| Garza, D | 1 |
| Zawadzki, R | 1 |
| Berman, L | 1 |
| Bushinsky, DA | 1 |
| Kwon, G | 1 |
| Lee, JH | 2 |
| Saunders, E | 1 |
| Bae, YS | 1 |
| Moon, SH | 1 |
| Lee, SJ | 2 |
| Cha, DR | 1 |
| de Morais, RB | 1 |
| do Couto Muniz, VP | 1 |
| Nunes Costa, E | 1 |
| Filho, SRF | 1 |
| Nakamura Hiraki, KR | 1 |
| Bispo-da-Silva, LB | 1 |
| Coelho Balbi, AP | 1 |
| Koszegi, S | 2 |
| Molnar, A | 2 |
| Lenart, L | 2 |
| Hodrea, J | 2 |
| Balogh, DB | 1 |
| Lakat, T | 1 |
| Szkibinszkij, E | 1 |
| Hosszu, A | 2 |
| Sparding, N | 1 |
| Genovese, F | 1 |
| Wagner, L | 2 |
| Vannay, A | 2 |
| Szabo, AJ | 2 |
| Fekete, A | 2 |
| Qiu, DD | 1 |
| Liu, J | 4 |
| Shi, JS | 1 |
| An, Y | 1 |
| Ge, YC | 1 |
| Zhou, ML | 1 |
| Kang, JS | 1 |
| Kim, JH | 2 |
| Son, SS | 1 |
| Cha, SK | 1 |
| Lee, ES | 1 |
| Chung, CH | 2 |
| Lee, EY | 2 |
| Looker, HC | 1 |
| Mauer, M | 6 |
| Saulnier, PJ | 3 |
| Harder, JL | 1 |
| Nair, V | 1 |
| Boustany-Kari, CM | 1 |
| Guarnieri, P | 1 |
| Hill, J | 1 |
| Esplin, CA | 1 |
| Kretzler, M | 1 |
| Nelson, RG | 6 |
| Najafian, B | 1 |
| Mavroeidi, V | 1 |
| Petrakis, I | 1 |
| Stylianou, K | 1 |
| Katsarou, T | 1 |
| Giannakakis, K | 1 |
| Perakis, K | 1 |
| Vardaki, E | 1 |
| Stratigis, S | 1 |
| Ganotakis, E | 1 |
| Papavasiliou, S | 1 |
| Daphnis, E | 1 |
| Weil, EJ | 4 |
| Fufaa, G | 1 |
| Jones, LI | 2 |
| Lovato, T | 2 |
| Lemley, KV | 4 |
| Hanson, RL | 2 |
| Knowler, WC | 3 |
| Bennett, PH | 2 |
| Yee, B | 3 |
| Myers, BD | 4 |
| Rauch, G | 1 |
| Beyersmann, J | 1 |
| Zhang, W | 1 |
| Miao, J | 1 |
| Wang, S | 2 |
| Zhang, Y | 4 |
| Jennifer Weil, E | 1 |
| Nagata, T | 1 |
| Fukuzawa, T | 1 |
| Takeda, M | 1 |
| Fukazawa, M | 1 |
| Mori, T | 1 |
| Nihei, T | 1 |
| Honda, K | 1 |
| Suzuki, Y | 1 |
| Kawabe, Y | 1 |
| Liu, Y | 1 |
| Jia, Z | 1 |
| Liu, S | 1 |
| Downton, M | 1 |
| Liu, G | 1 |
| Du, Y | 1 |
| Yang, T | 1 |
| Nicholas, SB | 1 |
| Iyengar, SK | 1 |
| Menon, MC | 1 |
| Chuang, PY | 1 |
| He, JC | 1 |
| Robiner, WN | 1 |
| Strand, TD | 2 |
| Reddy, MA | 1 |
| Sumanth, P | 1 |
| Lanting, L | 1 |
| Yuan, H | 1 |
| Wang, M | 1 |
| Mar, D | 1 |
| Bomsztyk, K | 1 |
| Natarajan, R | 1 |
| de Zeeuw, D | 23 |
| Fried, LF | 5 |
| Emanuele, N | 3 |
| Zhang, JH | 4 |
| Brophy, M | 2 |
| Conner, TA | 1 |
| Duckworth, W | 2 |
| Leehey, DJ | 3 |
| McCullough, PA | 2 |
| O'Connor, T | 2 |
| Palevsky, PM | 3 |
| Reilly, RF | 2 |
| Seliger, SL | 2 |
| Warren, SR | 2 |
| Watnick, S | 1 |
| Peduzzi, P | 2 |
| Guarino, P | 2 |
| Van Buren, PN | 1 |
| Adams-Huet, B | 3 |
| Nguyen, M | 1 |
| Molina, C | 1 |
| Toto, RD | 5 |
| Zhong, Y | 1 |
| Zhang, X | 1 |
| Cai, X | 1 |
| Wang, K | 2 |
| Chen, Y | 2 |
| Deng, Y | 1 |
| Best, M | 1 |
| de Wever, J | 1 |
| Smulders, Y | 1 |
| Izumi, Y | 1 |
| Kawahara, K | 1 |
| Nonoguchi, H | 1 |
| Nikolaidou, B | 1 |
| Lazaridis, A | 1 |
| Doumas, M | 1 |
| Quiroga, B | 1 |
| Fernández Juárez, G | 1 |
| Luño, J | 2 |
| Steurer, J | 1 |
| Riphagen, IJ | 1 |
| Deetman, PE | 1 |
| Bakker, SJ | 3 |
| Navis, G | 2 |
| Cooper, ME | 19 |
| Lewis, JB | 6 |
| Lambers Heerspink, HJ | 6 |
| Kakimoto, T | 1 |
| Okada, K | 1 |
| Hirohashi, Y | 1 |
| Relator, R | 1 |
| Kawai, M | 1 |
| Iguchi, T | 1 |
| Fujitaka, K | 1 |
| Nishio, M | 1 |
| Kato, T | 1 |
| Fukunari, A | 1 |
| Utsumi, H | 1 |
| Komers, R | 3 |
| Xu, B | 2 |
| Fu, Y | 1 |
| McClelland, A | 1 |
| Kantharidis, P | 1 |
| Mittal, A | 1 |
| Cohen, HT | 1 |
| Cohen, DM | 1 |
| Hull, TD | 1 |
| Agarwal, A | 1 |
| Castoldi, G | 1 |
| di Gioia, CR | 1 |
| Bombardi, C | 1 |
| Maestroni, S | 1 |
| Carletti, R | 1 |
| Steckelings, UM | 1 |
| Dahlöf, B | 2 |
| Unger, T | 1 |
| Zerbini, G | 1 |
| Stella, A | 1 |
| Jourdan, T | 1 |
| Szanda, G | 1 |
| Rosenberg, AZ | 1 |
| Tam, J | 1 |
| Earley, BJ | 1 |
| Godlewski, G | 1 |
| Cinar, R | 1 |
| Liu, Z | 1 |
| Ju, C | 1 |
| Pacher, P | 1 |
| Kunos, G | 1 |
| Pan, Y | 4 |
| Qiao, QY | 1 |
| Pan, LH | 1 |
| Zhou, DC | 1 |
| Hu, C | 1 |
| Gu, HF | 1 |
| Fu, SK | 1 |
| Liu, XL | 1 |
| Jin, HM | 4 |
| Kröpelin, TF | 1 |
| Andress, DL | 1 |
| Bijlsma, MJ | 1 |
| Persson, F | 4 |
| Parving, HH | 31 |
| Heerspink, HJ | 2 |
| Schutte, E | 1 |
| Lutgers, HL | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Gansevoort, RT | 2 |
| Cavusoglu, T | 1 |
| Karadeniz, T | 1 |
| Cagiltay, E | 1 |
| Karadeniz, M | 1 |
| Yigitturk, G | 1 |
| Acikgoz, E | 1 |
| Uyanikgil, Y | 1 |
| Ates, U | 1 |
| Tuglu, MI | 1 |
| Erbas, O | 1 |
| Ezel, T | 1 |
| Kocyigit, Y | 1 |
| Deveci, E | 1 |
| Atamer, Y | 1 |
| Sermet, A | 1 |
| Uysal, E | 1 |
| Aktaş, A | 1 |
| Yavuz, D | 2 |
| Emanuele, NV | 1 |
| Whaley-Connell, A | 2 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 3 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Mugendi, GA | 1 |
| Nyamu, DG | 1 |
| Okalebo, FA | 1 |
| Nyamweya, NN | 1 |
| Ndwiga, S | 1 |
| Mwangi, M | 1 |
| Anbar, HS | 1 |
| Shehatou, GS | 1 |
| Suddek, GM | 1 |
| Gameil, NM | 1 |
| Xu, HZ | 1 |
| Wang, WN | 1 |
| Zhang, YY | 1 |
| Cheng, YL | 1 |
| Xu, ZG | 1 |
| Gellai, R | 1 |
| Balogh, D | 1 |
| Ver, A | 1 |
| Banki, NF | 1 |
| Fulop, N | 1 |
| Zhu, Q | 1 |
| Qi, X | 1 |
| Wu, Y | 1 |
| Srivastava, A | 1 |
| Vega, GL | 2 |
| Wheelock, KM | 2 |
| Howell, S | 1 |
| Tanamas, SK | 2 |
| Beisswenger, PJ | 1 |
| Fufaa, GD | 1 |
| Zhu, X | 1 |
| Zhang, C | 1 |
| Fan, Q | 1 |
| Liu, X | 2 |
| Yang, G | 1 |
| Jiang, Y | 1 |
| Wang, L | 2 |
| Lewis, EJ | 4 |
| Hollenberg, NK | 3 |
| Ingelfinger, JR | 3 |
| Satoh, M | 1 |
| Fujimoto, S | 1 |
| Arakawa, S | 1 |
| Yada, T | 1 |
| Namikoshi, T | 1 |
| Haruna, Y | 1 |
| Horike, H | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Zhou, QL | 1 |
| Peng, WS | 1 |
| Yuichiro, Y | 1 |
| Liu, ZC | 1 |
| Yang, JH | 1 |
| Xu, JY | 1 |
| Tao, LJ | 1 |
| Ning, WB | 1 |
| Liu, JS | 1 |
| Zhang, Z | 24 |
| Ning, G | 3 |
| Deb, DK | 3 |
| Kong, J | 3 |
| Li, YC | 3 |
| Teles, F | 1 |
| Machado, FG | 1 |
| Ventura, BH | 1 |
| Malheiros, DM | 1 |
| Fujihara, CK | 1 |
| Silva, LF | 1 |
| Zatz, R | 3 |
| Ikeda, H | 1 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Anderson, S | 2 |
| Woo, KT | 1 |
| Chan, CM | 1 |
| Wong, KS | 2 |
| Huang, GD | 1 |
| Seliger, S | 1 |
| Guo, LL | 1 |
| Müller, D | 1 |
| Müller, DN | 1 |
| Takahashi, K | 1 |
| Agha, A | 2 |
| Amer, W | 1 |
| Anwar, E | 2 |
| Bashir, K | 2 |
| Bichu, P | 1 |
| Nistala, R | 1 |
| Khan, A | 1 |
| Sowers, JR | 2 |
| Marshall, SM | 1 |
| Wang, Y | 2 |
| Li, G | 1 |
| Strugnell, S | 1 |
| Sabbagh, Y | 1 |
| Arbeeny, C | 1 |
| Zinman, B | 3 |
| Gardiner, R | 3 |
| Suissa, S | 3 |
| Sinaiko, A | 1 |
| Strand, T | 2 |
| Drummond, K | 1 |
| Donnelly, S | 1 |
| Goodyer, P | 2 |
| Gubler, MC | 1 |
| Klein, R | 3 |
| Arozal, W | 1 |
| Watanabe, K | 1 |
| Veeraveedu, PT | 1 |
| Ma, M | 1 |
| Thandavarayan, RA | 1 |
| Suzuki, K | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| González F, F | 1 |
| Fuentes C, V | 1 |
| Castro H, C | 1 |
| Santelices L, JP | 1 |
| Lorca H, E | 1 |
| Masuda, S | 1 |
| Tamura, K | 1 |
| Wakui, H | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Maeda, A | 1 |
| Dejima, T | 1 |
| Yanagi, M | 1 |
| Azuma, K | 1 |
| Umemura, S | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Mehdi, UF | 1 |
| Raskin, P | 1 |
| Bramlage, P | 2 |
| Schindler, C | 1 |
| Hoque, R | 1 |
| Rahman, MS | 1 |
| Iqbal, M | 1 |
| Sun, T | 1 |
| Wong, KE | 1 |
| Shi, H | 1 |
| Chang, A | 1 |
| Tan, F | 1 |
| Mukherjee, JJ | 1 |
| Lee, KO | 1 |
| Lim, P | 1 |
| Liew, CF | 1 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Lai, ZF | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 2 |
| Fukuda, M | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Sung, JK | 1 |
| Koh, JH | 1 |
| Lee, MY | 1 |
| Kim, BH | 1 |
| Nam, SM | 1 |
| Yoo, JH | 1 |
| Kim, SH | 1 |
| Hong, SW | 1 |
| Choi, R | 1 |
| Naviglio, S | 1 |
| Pirozzi, F | 1 |
| Wang, H | 1 |
| Deng, JL | 1 |
| Yue, J | 1 |
| Hou, YB | 1 |
| Dragović, T | 1 |
| Ajdinović, B | 1 |
| Hrvacević, R | 1 |
| Ilić, V | 1 |
| Magić, Z | 1 |
| Andelković, Z | 1 |
| Kocev, N | 1 |
| Agarwal, R | 1 |
| Siragy, HM | 2 |
| Fujiwara, N | 1 |
| Sato, E | 1 |
| Ueda, Y | 1 |
| Sugaya, T | 1 |
| Koide, H | 1 |
| Rossing, P | 13 |
| Visavadiya, NP | 1 |
| Li, Y | 1 |
| Rahimi, Z | 1 |
| Felehgari, V | 1 |
| Rahimi, M | 1 |
| Mozafari, H | 1 |
| Yari, K | 1 |
| Vaisi-Raygani, A | 1 |
| Rezaei, M | 1 |
| Malek-Khosravi, S | 1 |
| Khazaie, H | 1 |
| Kujal, P | 1 |
| Chábová, VČ | 1 |
| Vernerová, Z | 1 |
| Walkowska, A | 1 |
| Kompanowska-Jezierska, E | 1 |
| Sadowski, J | 1 |
| Vaňourková, Z | 1 |
| Husková, Z | 1 |
| Opočenský, M | 1 |
| Skaroupková, P | 1 |
| Schejbalová, S | 1 |
| Kramer, HJ | 1 |
| Rakušan, D | 1 |
| Malý, J | 1 |
| Netuka, I | 1 |
| Vaněčková, I | 1 |
| Kopkan, L | 1 |
| Cervenka, L | 1 |
| Miao, Y | 2 |
| Dobre, D | 1 |
| Brenner, BM | 26 |
| Shahinfar, S | 29 |
| Grobbee, D | 1 |
| Oyama, TT | 1 |
| Beard, DR | 1 |
| Tikellis, C | 1 |
| Lotspeich, DF | 1 |
| Titan, SM | 2 |
| Graciolli, FG | 1 |
| dos Reis, LM | 1 |
| Barros, RT | 2 |
| Jorgetti, V | 1 |
| Moysés, RM | 1 |
| Nielsen, SE | 1 |
| Andersen, S | 13 |
| Zdunek, D | 1 |
| Hess, G | 1 |
| de Graeff, PA | 2 |
| Laverman, GD | 3 |
| Berl, T | 2 |
| Remuzzi, G | 13 |
| Packham, D | 1 |
| Thomas, MC | 1 |
| Hillege, HJ | 1 |
| de Portu, S | 1 |
| Citarella, A | 1 |
| Cammarota, S | 1 |
| Menditto, E | 1 |
| Mantovani, LG | 1 |
| Ottenbros, SA | 1 |
| Grobbee, DE | 1 |
| Gonçalves, AR | 1 |
| El Nahas, AM | 1 |
| Doria, A | 1 |
| Krolewski, AS | 1 |
| Fujita, H | 1 |
| Sakamoto, T | 1 |
| Komatsu, K | 1 |
| Fujishima, H | 1 |
| Morii, T | 1 |
| Narita, T | 1 |
| Takahashi, T | 1 |
| Yamada, Y | 1 |
| M Vieira, J | 1 |
| Dominguez, WV | 1 |
| Manni, ME | 1 |
| Bigagli, E | 1 |
| Lodovici, M | 1 |
| Zazzeri, M | 1 |
| Raimondi, L | 1 |
| Dhaun, N | 1 |
| Webb, DJ | 1 |
| Lo, CS | 1 |
| Liu, F | 2 |
| Shi, Y | 1 |
| Maachi, H | 1 |
| Chenier, I | 2 |
| Godin, N | 1 |
| Filep, JG | 2 |
| Zhang, SL | 2 |
| Chan, JS | 2 |
| Rasi Hashemi, S | 1 |
| Noshad, H | 1 |
| Tabrizi, A | 1 |
| Mobasseri, M | 1 |
| Tayebi Khosroshahi, H | 1 |
| Heydarnejad, M | 1 |
| Khalaj, MR | 1 |
| Aghamohammadzadeh, N | 1 |
| Adam, WR | 1 |
| Garcia-Touza, M | 1 |
| Ring, T | 1 |
| Hirsch, S | 1 |
| Smink, PA | 1 |
| Futrakul, N | 1 |
| Futrakul, P | 1 |
| Mason, CC | 1 |
| Blouch, K | 2 |
| Richardson, M | 1 |
| Satchell, SC | 1 |
| Juhl, TR | 4 |
| Deinum, J | 3 |
| Zanella, MT | 1 |
| Ribeiro, AB | 4 |
| Suzuki, H | 3 |
| Dickson, TZ | 4 |
| Ahmed, T | 1 |
| Ramjit, D | 4 |
| Smith, RD | 1 |
| Gerth, WC | 4 |
| Viberti, G | 1 |
| Hannedouche, T | 2 |
| Martinez-Castelao, A | 1 |
| Carides, GW | 7 |
| Brenner, B | 1 |
| Jacobsen, P | 1 |
| Tarnow, L | 8 |
| Eberhard, R | 1 |
| Dikow, R | 2 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Drummond, KN | 1 |
| Donnelly, SM | 2 |
| Kramer, MS | 2 |
| Sinaiko, AR | 2 |
| Herman, WH | 2 |
| Dasbach, EJ | 2 |
| Alexander, CM | 3 |
| Cook, JR | 1 |
| Keane, WF | 15 |
| Lyle, PA | 7 |
| Souchet, T | 1 |
| Durand Zaleski, I | 1 |
| Rodier, M | 1 |
| Gaugris, S | 1 |
| Passa, P | 1 |
| Cambien, F | 2 |
| Qin, J | 1 |
| Sun, L | 1 |
| Hu, L | 1 |
| Cao, Z | 1 |
| Shanifar, S | 1 |
| Douglas, J | 1 |
| van Dijk, DJ | 1 |
| Sidorenko, BA | 2 |
| Preobrazhenskiĭ, DV | 2 |
| Stetsenko, TM | 2 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Küçükkaya, B | 2 |
| Haklar, G | 1 |
| Ersöz, O | 2 |
| Akoğlu, E | 1 |
| Akalin, S | 2 |
| Yang, L | 1 |
| Fan, J | 1 |
| Mi, X | 1 |
| Xu, G | 1 |
| Murali, B | 2 |
| Umrani, DN | 1 |
| Goyal, RK | 2 |
| Huang, YH | 1 |
| Wang, HT | 1 |
| Zhu, QZ | 1 |
| Zhang, H | 1 |
| Shen, W | 1 |
| Krantz, MJ | 1 |
| Stanton, R | 1 |
| Kubba, S | 1 |
| Agarwal, SK | 1 |
| Prakash, A | 1 |
| Puri, V | 1 |
| Babbar, R | 1 |
| Anuradha, S | 1 |
| Wittchen, HU | 1 |
| Pittrow, D | 1 |
| Kirch, W | 1 |
| Lehnert, H | 1 |
| Ritz, E | 1 |
| Onuigbo, MA | 1 |
| Ruilope, LM | 2 |
| Segura, J | 1 |
| Foreman, BH | 1 |
| Chambliss, ML | 1 |
| Ferrario, C | 1 |
| Abdelhamed, AI | 1 |
| Moore, M | 1 |
| Rayner, B | 1 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Chan, JC | 3 |
| Wat, NM | 1 |
| So, WY | 2 |
| Lam, KS | 1 |
| Chua, CT | 1 |
| Morad, Z | 1 |
| Hille, D | 1 |
| Kurokawa, K | 4 |
| Kumar, D | 2 |
| Zimpelmann, J | 2 |
| Robertson, S | 1 |
| Burns, KD | 2 |
| Kanno, Y | 1 |
| Kaneko, K | 1 |
| Kaneko, M | 1 |
| Kotaki, S | 1 |
| Mimura, T | 1 |
| Takane, H | 1 |
| Snapinn, S | 2 |
| Mitch, WE | 5 |
| Burgess, ED | 1 |
| Marentette, MA | 1 |
| Chabot, I | 1 |
| Sasaki, M | 1 |
| Uehara, S | 1 |
| Ohta, H | 1 |
| Taguchi, K | 1 |
| Kemi, M | 1 |
| Nishikibe, M | 1 |
| Matsumoto, H | 1 |
| Cetinkaya, R | 1 |
| Odabas, AR | 1 |
| Selcuk, Y | 1 |
| Perico, N | 1 |
| Ruggenenti, P | 3 |
| Awad, AS | 1 |
| Webb, RL | 1 |
| Carey, RM | 1 |
| Leung, WY | 1 |
| Tong, PC | 1 |
| Lo, MK | 1 |
| Lee, KF | 1 |
| Ko, GT | 1 |
| Chan, WB | 1 |
| Cockram, CS | 1 |
| Critchley, JA | 1 |
| Wang, HY | 1 |
| Chen, YP | 1 |
| Mohanram, A | 2 |
| Hunsicker, LG | 1 |
| Nakao, N | 1 |
| Senou, H | 1 |
| Kasuga, H | 1 |
| Toriyama, T | 1 |
| Kawahara, H | 1 |
| Szucs, TD | 1 |
| Sandoz, MS | 1 |
| Keusch, GW | 1 |
| Schjoedt, KJ | 2 |
| Perna, A | 1 |
| Dimitrov, BD | 1 |
| Hille, DA | 1 |
| Wan, X | 1 |
| Huang, HH | 1 |
| Li, JG | 1 |
| Egan, B | 1 |
| Gleim, G | 1 |
| Panish, J | 1 |
| Isreb, MA | 1 |
| Marcic, S | 1 |
| Singh, AK | 1 |
| Singh, R | 1 |
| Kowey, PR | 3 |
| Shlipak, M | 1 |
| Gleim, GW | 2 |
| Mogensen, CE | 1 |
| Snapinn, SM | 4 |
| van Nieuwenhoven, FA | 1 |
| Rossing, K | 1 |
| Wieten, L | 1 |
| Goldschmeding, R | 1 |
| Sica, DA | 1 |
| Gehr, TW | 1 |
| Ghosh, S | 1 |
| Boner, G | 1 |
| McCarroll, K | 1 |
| Dickson, T | 1 |
| Crow, RS | 1 |
| Wolf, G | 1 |
| Rodríguez-Iturbe, B | 1 |
| Quiroz, Y | 1 |
| Shahkarami, A | 1 |
| Li, Z | 1 |
| Parvanova, A | 1 |
| Chiurchiu, C | 1 |
| Seng, WK | 1 |
| Hwang, SJ | 1 |
| Han, DC | 1 |
| Teong, CC | 1 |
| Chan, J | 2 |
| Burke, TA | 1 |
| Choi, YJ | 1 |
| Carr, AA | 1 |
| Devereux, RB | 1 |
| Ibsen, H | 1 |
| Lindholm, LH | 1 |
| Edelman, JM | 1 |
| Burnier, M | 1 |
| Zanchi, A | 1 |
| Zandbergen, AA | 1 |
| Lamberts, SW | 1 |
| Baggen, MG | 1 |
| Janssen, JA | 1 |
| Boersma, E | 1 |
| Bootsma, AH | 1 |
| Sugaru, E | 2 |
| Ono-Kishino, M | 2 |
| Nagamine, J | 2 |
| Tokunaga, T | 2 |
| Kitoh, M | 2 |
| Hume, WE | 2 |
| Nagata, R | 2 |
| Taiji, M | 2 |
| Lash, JP | 1 |
| Lajer, M | 2 |
| Gavras, H | 1 |
| Izquierdo, A | 1 |
| López-Luna, P | 1 |
| Ortega, A | 1 |
| Romero, M | 1 |
| Guitiérrez-Tarrés, MA | 1 |
| Arribas, I | 1 |
| Alvarez, MJ | 1 |
| Esbrit, P | 1 |
| Bosch, RJ | 1 |
| Igarashi, M | 1 |
| Hirata, A | 1 |
| Kadomoto, Y | 1 |
| Tominaga, M | 1 |
| Moss, SE | 1 |
| Winkelmayer, WC | 1 |
| Avorn, J | 1 |
| Kimura, G | 1 |
| Ning, JP | 1 |
| Yang, S | 1 |
| Ning, C | 1 |
| Zeng, YH | 1 |
| Liu, LZ | 1 |
| Eijkelkamp, WB | 1 |
| Lim, SC | 1 |
| Koh, AF | 1 |
| Goh, SK | 1 |
| Chua, CL | 1 |
| Heng, BL | 1 |
| Subramaniam, T | 1 |
| Sum, CF | 1 |
| Sawaki, H | 1 |
| Terasaki, J | 1 |
| Fujita, A | 1 |
| Nakagawa, S | 1 |
| Kanatsuna, N | 1 |
| Sadahiro, K | 1 |
| Isotani, H | 1 |
| Imagawa, A | 1 |
| Hanafusa, T | 1 |
| Abe, H | 1 |
| Minatoguchi, S | 1 |
| Ohashi, H | 1 |
| Murata, I | 1 |
| Minagawa, T | 1 |
| Okuma, T | 1 |
| Yokoyama, H | 1 |
| Takatsu, H | 1 |
| Takaya, T | 1 |
| Nagano, T | 1 |
| Osumi, Y | 1 |
| Kakami, M | 1 |
| Tsukamoto, T | 1 |
| Tanaka, T | 1 |
| Hiei, K | 1 |
| Fujiwara, H | 1 |
| Brezniceanu, ML | 1 |
| Wei, CC | 1 |
| Sachetelli, S | 1 |
| Tershakovec, AM | 1 |
| Appel, GB | 1 |
| McGill, JB | 2 |
| Tufescu, A | 1 |
| Kanazawa, M | 1 |
| Ishida, A | 1 |
| Lu, H | 1 |
| Sasaki, Y | 1 |
| Ootaka, T | 1 |
| Sato, T | 1 |
| Kohzuki, M | 1 |
| Liu, N | 1 |
| Lunceford, J | 1 |
| Wong, PH | 1 |
| Portero-Otín, M | 1 |
| Pamplona, R | 1 |
| Boada, J | 1 |
| Jové, M | 1 |
| Gonzalo, H | 1 |
| Buleon, M | 1 |
| Linz, W | 1 |
| Schäfer, S | 1 |
| Tack, I | 1 |
| Girolami, JP | 1 |
| Kageyama, S | 1 |
| Cristovam, PC | 1 |
| Arnoni, CP | 1 |
| de Andrade, MC | 1 |
| Casarini, DE | 1 |
| Pereira, LG | 1 |
| Schor, N | 1 |
| Boim, MA | 1 |
| Bakris, G | 1 |
| Burgess, E | 1 |
| Weir, M | 1 |
| Davidai, G | 1 |
| Koval, S | 1 |
| de Jong, PE | 2 |
| Pichler, M | 1 |
| Klein, W | 1 |
| Huber, K | 1 |
| Pachinger, O | 1 |
| Yotsumoto, T | 1 |
| Naitoh, T | 1 |
| Shikada, K | 1 |
| Tanaka, S | 1 |
| Birck, R | 1 |
| Keim, V | 1 |
| Fiedler, F | 1 |
| van der Woude, FJ | 1 |
| Rohmeiss, P | 1 |
| Hebert, LA | 1 |
| Falkenhain, ME | 1 |
| Nahman, NS | 1 |
| Cosio, FG | 1 |
| O'Dorisio, TM | 1 |
| Yavuz, DG | 1 |
| Budak, Y | 1 |
| Ahiskali, R | 1 |
| Ekicioglu, G | 1 |
| Emerk, K | 1 |
| Hansen, BV | 1 |
| Bos, H | 1 |
| Schalkwijk, CG | 1 |
| Stehouwer, CD | 1 |
| Lacourcière, Y | 1 |
| Bélanger, A | 1 |
| Godin, C | 1 |
| Hallé, JP | 1 |
| Ross, S | 1 |
| Wright, N | 1 |
| Marion, J | 1 |
| Bialek, J | 1 |
| Deckert, M | 1 |
| Levine, DZ | 1 |
| Wehbi, G | 1 |
| Imig, JD | 1 |
| Navar, LG | 1 |
| Kuriyama, S | 1 |
| Tomonari, H | 1 |
| Abe, A | 1 |
| Imasawa, T | 1 |
| Hosoya, T | 1 |
| Hauser, AC | 1 |
| Hörl, WH | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Bloomgarden, ZT | 1 |
| Kurtzman, NA | 1 |
| Jerums, G | 1 |
| Gilbert, RE | 1 |
| Atkins, RC | 1 |
| Pierce, HL | 1 |
| Stevermer, JJ | 1 |
| Farquhar, D | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Nilsson, P | 1 |
| Attvall, S | 1 |
| Walser, M | 1 |
| Ceriello, A | 1 |
| Motz, E | 1 |
| de Pablos-Velasco, PL | 1 |
| Pazos Toral, F | 1 |
| Esmatjes, JE | 1 |
| Fernandez-Vega, F | 1 |
| Lopez de la Torre, ML | 1 |
| Pozuelo, A | 1 |
| Grunfeld, JP | 1 |
| Schluchter, MD | 1 |
| Snavely, D | 1 |
| Simpson, R | 1 |
| Doggrell, SA | 1 |
| Lindenfeld, J | 1 |
| Borer, J | 1 |
| Armstrong, PW | 1 |
| Studney, D | 1 |
| Os, I | 1 |
| Stenehjem, A | 1 |
| Høieggen, A | 1 |
| Draganov, B | 1 |
| Jenssen, T | 1 |
| Holdaas, H | 1 |
| Goicolea, I | 1 |
| Fernández González, R | 1 |
| Piniés, J | 1 |
| Garrido, J | 1 |
| Martínez, JM | 1 |
| Armenteros, S | 1 |
| Moreno Carretero, E | 1 |
| Kuhlmann, MK | 1 |
| Köhler, H | 1 |
| Tan, K | 1 |
| Chow, WS | 1 |
| Wong, Y | 1 |
| Shiu, S | 1 |
| Tam, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage[NCT03009864] | Early Phase 1 | 632 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and[NCT01371747] | Phase 2 | 324 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| Renin Angiotensin System Blockage-DN (RASS)[NCT00143949] | Phase 2 | 285 participants (Actual) | Interventional | 1997-03-31 | Completed | ||
| CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)[NCT00555217] | Phase 3 | 1,448 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to It was stopped primarily because of safety concerns along with low conditional power to detect a treatment effect on the primary outcome.) | ||
| Improving Outcomes in Diabetic Nephropathy[NCT00381134] | Phase 2 | 92 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan[NCT00774904] | 80 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria[NCT00097955] | Phase 2 | 496 participants | Interventional | 2004-10-31 | Completed | ||
| Protein Profile of Immunoregulatory Factors in Diabetic Cataract[NCT01832311] | Phase 4 | 61 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus[NCT00419835] | Phase 4 | 80 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes Mellitus and Nephropathy[NCT00308347] | Phase 3 | 1,513 participants (Actual) | Interventional | 1996-05-31 | Completed | ||
| [NCT03019848] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) (DKD-TMT)[NCT02176278] | 2,400 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Angiotensin Converting Enzyme Inhibitors & Angiotensin Receptor Blocker in the Treatment of Type 2 Diabetic Patients Adverse Drug Effects and Drug Interactions- a Survey in an Internal Medicine Department.[NCT00437775] | 300 participants | Observational | 2007-01-31 | Recruiting | |||
| A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS® (Telmisartan) 80 mg Versus COZAAR® (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt N[NCT00168857] | Phase 4 | 860 participants (Actual) | Interventional | 2003-07-09 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI)[NCT05037695] | Phase 4 | 40 participants (Anticipated) | Interventional | 2021-07-21 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Least squares mean changes from Baseline to Day 3 were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Day 3
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.26 |
| Stratum 1: 16.8 g/d Patiromer | -0.28 |
| Stratum 1: 25.2 g/d Patiromer | -0.31 |
| Stratum 2: 16.8 g/d Patiromer | -0.65 |
| Stratum 2: 25.2 g/d Patiromer | -0.59 |
| Stratum 2: 33.6 g/d Patiromer | -0.53 |
Least square mean changes from Baseline to Week 4/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 4 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.51 |
| Stratum 1: 25.2 g/d Patiromer | -0.55 |
| Stratum 2: 16.8 g/d Patiromer | -0.87 |
| Stratum 2: 25.2 g/d Patiromer | -0.97 |
| Stratum 2: 33.6 g/d Patiromer | -0.92 |
Least squares mean changes from Baseline to Week 8/first titration were derived from parallel lines ANCOVA model with randomized starting dose and baseline serum potassium value as covariates. (NCT01371747)
Timeframe: Baseline to Week 8 or First Titration which could occur at any scheduled study visit after patiromer initiation.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.35 |
| Stratum 1: 16.8 g/d Patiromer | -0.47 |
| Stratum 1: 25.2 g/d Patiromer | -0.54 |
| Stratum 2: 16.8 g/d Patiromer | -0.88 |
| Stratum 2: 25.2 g/d Patiromer | -0.95 |
| Stratum 2: 33.6 g/d Patiromer | -0.91 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | -0.54 |
| Stratum 1: 16.8 g/d Patiromer | -0.44 |
| Stratum 1: 25.2 g/d Patiromer | -0.50 |
| Stratum 2: 16.8 g/d Patiromer | -1.00 |
| Stratum 2: 25.2 g/d Patiromer | -0.96 |
| Stratum 2: 33.6 g/d Patiromer | -1.17 |
(NCT01371747)
Timeframe: Week 52 or Last Patiromer Dose (if Occurred before Week 52) to Following up Visit Plus 7 Days
| Intervention | mEq/L (Mean) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 0.36 |
| Stratum 1: 16.8 g/d Patiromer | 0.22 |
| Stratum 1: 25.2 g/d Patiromer | 0.30 |
| Stratum 2: 16.8 g/d Patiromer | 0.41 |
| Stratum 2: 25.2 g/d Patiromer | 0.39 |
| Stratum 2: 33.6 g/d Patiromer | 0.58 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 100 |
| Stratum 1: 16.8 g/d Patiromer | 100 |
| Stratum 1: 25.2 g/d Patiromer | 98.4 |
| Stratum 2: 16.8 g/d Patiromer | 91.7 |
| Stratum 2: 25.2 g/d Patiromer | 95.8 |
| Stratum 2: 33.6 g/d Patiromer | 95.5 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 95.2 |
| Stratum 1: 16.8 g/d Patiromer | 90.8 |
| Stratum 1: 25.2 g/d Patiromer | 81.3 |
| Stratum 2: 16.8 g/d Patiromer | 79.2 |
| Stratum 2: 25.2 g/d Patiromer | 91.7 |
| Stratum 2: 33.6 g/d Patiromer | 77.3 |
(NCT01371747)
Timeframe: Baseline to Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 86.3 |
| Stratum 1: 16.8 g/d Patiromer | 81.6 |
| Stratum 1: 25.2 g/d Patiromer | 88.9 |
| Stratum 2: 16.8 g/d Patiromer | 86.7 |
| Stratum 2: 25.2 g/d Patiromer | 89.5 |
| Stratum 2: 33.6 g/d Patiromer | 93.3 |
(NCT01371747)
Timeframe: Baseline to Week 8
| Intervention | Days (Median) |
|---|---|
| Stratum 1: 8.4 g/d Patiromer | 4 |
| Stratum 1: 16.8 g/d Patiromer | 4 |
| Stratum 1: 25.2 g/d Patiromer | 4 |
| Stratum 2: 16.8 g/d Patiromer | 8 |
| Stratum 2: 25.2 g/d Patiromer | 7.5 |
| Stratum 2: 33.6 g/d Patiromer | 8 |
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
Time to the first event of reduction in estimated GFR of 30ml/min/1.73m*m in individuals w/a baseline estimated GFR >= 60 ml/min/1.73m*m, reduction in estimated GFR >50% in individuals w/ baseline estimated GFR <60ml/min/1.73m*m; ESRD or death. (NCT00555217)
Timeframe: From enrollemnt to time of first primary event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 132 |
| Monotherapy ARB | 152 |
Time to the first event of reduction in estimated GFR of >50% (for individuals with baseline GFR <60) or reduction in GFR of >30 (for individuals with baseline GFR >= GFR 60) or ESRD. (NCT00555217)
Timeframe: From enrollment to time of first event, up to 4.5 years
| Intervention | participants (Number) |
|---|---|
| Combination of ARB and ACEI | 77 |
| Monotherapy ARB | 101 |
39 reviews available for losartan and Diabetic Nephropathies
| Article | Year |
|---|---|
Inhibition of the renin-angiotensin system: is more better?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Dose-Response Relationship | 2009 |
[Multi-national clinical trial in circulatory disorders].
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-B | 2009 |
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabe | 2009 |
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Com | 2010 |
Prostaglandin E1 for preventing the progression of diabetic kidney disease.
Topics: Albuminuria; Alprostadil; Diabetic Nephropathies; Disease Progression; Drugs, Chinese Herbal; Fosino | 2010 |
Comparing angiotensin II receptor blockers on benefits beyond blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis | 2010 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
Evidence-based hypertension treatment in patients with diabetes.
Topics: Albuminuria; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Va | 2012 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; | 2002 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diab | 2004 |
AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Diabetic Nephro | 2004 |
Advances in the treatment of diabetic renal disease: focus on losartan.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabe | 2004 |
Angiotensin type 1 receptor blockers in chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephrop | 2004 |
Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
[Kidney and hypertension--evidence based medicine].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Glucose; Captopril; Diabetic Nep | 2004 |
Clinical pharmacokinetics of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2005 |
[Renin-angiotensin system in diabetic nephropathy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2005 |
[The renin-angiotensin-aldosterone system -- more complex as previously thought].
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2005 |
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2005 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2006 |
Losartan: lessons learned from the RENAAL study.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cli | 2006 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2006 |
[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
[Inhibition of the renin-angiotensin system: ACE inhibitors and angiotensin II receptor blockers].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1996 |
[Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykin | 2001 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; D | 2001 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calci | 2002 |
93 trials available for losartan and Diabetic Nephropathies
| Article | Year |
|---|---|
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2022 |
Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Case-Control Studies; China; Diabetic Nephropathi | 2019 |
Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Drugs, Chinese Herbal; Glomerular Fi | 2020 |
Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy.
Topics: Atrial Natriuretic Factor; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dr | 2018 |
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Diabe | 2018 |
Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.
Topics: Adult; Albuminuria; Analysis of Variance; Biopsy, Needle; Diabetes Mellitus, Type 2; Diabetic Nephro | 2019 |
Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Indians, North Ameri | 2013 |
Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Biopsy; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2013 |
Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic N | 2013 |
Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction.
Topics: 3T3-L1 Cells; Adipocytes; Aged; Amlodipine; Animals; Antihypertensive Agents; Diabetic Nephropathies | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2015 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Crea | 2016 |
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.
Topics: Diabetic Nephropathies; Female; Humans; Lipoproteins; Losartan; Male; Middle Aged; Spironolactone; T | 2016 |
Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glycat | 2016 |
Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial.
Topics: Adult; Albumins; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; | 2016 |
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Amides; Angiotensin II Type 1 Receptor Bloc | 2008 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus | 2009 |
Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Topics: Adiponectin; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabe | 2009 |
Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus | 2009 |
Renal and retinal effects of enalapril and losartan in type 1 diabetes.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Benzimidazol | 2009 |
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor | 2009 |
Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Humans; | 2009 |
Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2010 |
Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabet | 2010 |
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2010 |
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2011 |
FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2011 |
Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabe | 2011 |
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Diab | 2011 |
Pharmaco-economic consequences of losartan therapy in patients undergoing diabetic end stage renal disease in EU and USA.
Topics: Adult; Aged; Antihypertensive Agents; Cost Savings; Cost-Benefit Analysis; Diabetic Nephropathies; E | 2011 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2011 |
Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antioxidant | 2011 |
ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bi | 2011 |
Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Topics: Acetylcysteine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Dia | 2012 |
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Inter | 2012 |
Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biopsy; Capillaries; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Creatinine; Diabetes | 2002 |
Losartan in diabetic nephropathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; | 2003 |
ACE-I and ARBs in early diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Diabetes | 2002 |
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2003 |
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Topics: Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney | 2003 |
An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.
Topics: Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Dia | 2003 |
Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2003 |
Blood pressure and diabetic nephropathy.
Topics: Antihypertensive Agents; Blood Pressure; Diabetic Nephropathies; Humans; Hypertension; Losartan; Pla | 2003 |
Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics.
Topics: Adult; Albuminuria; Antihypertensive Agents; Autonomic Nervous System Diseases; Diabetes Mellitus, T | 2003 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Topics: Antihypertensive Agents; Asian People; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium; Diabetes Mellitus, | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2004 |
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Canada; Cost Savings; Diabetes Mellitus, Type 2; Diab | 2004 |
Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2004 |
The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asian People; Creatinine; Critical Care; Diabetes Mel | 2004 |
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.
Topics: Aged; Albuminuria; Angina, Unstable; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Cardiovasc | 2004 |
[Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture].
Topics: Adult; Albuminuria; Astragalus propinquus; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, | 2004 |
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy.
Topics: Aged; Anemia; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Pr | 2004 |
The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 2 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit An | 2004 |
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Health Care | 2004 |
Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
Topics: Adult; Albuminuria; Aldosterone; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Melli | 2004 |
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
Topics: Aged; Antihypertensive Agents; Cost Savings; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fema | 2004 |
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Metho | 2004 |
Losartan and end-organ protection--lessons from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2005 |
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Topics: Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diab | 2005 |
Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Cost-Benefit Analysi | 2005 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Diabetes Mellitus, | 2006 |
Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cytochrome P-450 CYP11B | 2006 |
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 2006 |
The relation of ambulatory blood pressure and pulse rate to retinopathy in type 1 diabetes mellitus: the renin-angiotensin system study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pres | 2006 |
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fe | 2006 |
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Creatinine; | 2006 |
Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; C-Peptide; Calcium | 2007 |
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Topics: Aged; Albuminuria; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2007 |
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Com | 2007 |
Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angio | 2007 |
A renoprotective effect of low dose losartan in patients with type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Mass Index; D | 2008 |
Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2007 |
The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2008 |
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2008 |
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressur | 2008 |
Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2000 |
Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Neph | 2000 |
Glomerular permselectivity in early stages of overt diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Diabetic Nephropathies; Female; Ficoll; Humans; Kidney Glom | 2000 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cre | 2001 |
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2001 |
Losartan titration versus diuretic combination in type 2 diabetic patients.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellit | 2002 |
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).
Topics: Aged; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Bl | 2000 |
Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diabetic Nephropat | 2002 |
[Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study].
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antih | 2002 |
Effect of losartan on plasma C-reactive protein in type 2 diabetic patients with microabluminuria.
Topics: Albuminuria; Antihypertensive Agents; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephro | 2002 |
146 other studies available for losartan and Diabetic Nephropathies
| Article | Year |
|---|---|
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimen | 2018 |
Pathophysiological analysis of uninephrectomized db/db mice as a model of severe diabetic kidney disease.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; | 2022 |
Pentosan polysulfate exerts anti-inflammatory effect and halts albuminuria progression in diabetic nephropathy: Role of combined losartan.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2022 |
Pan-Src kinase inhibitor treatment attenuates diabetic kidney injury via inhibition of Fyn kinase-mediated endoplasmic reticulum stress.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Fibr | 2022 |
Effect of crocin and losartan on biochemical parameters and genes expression of FRMD3 and BMP7 in diabetic rats.
Topics: Animals; Bone Morphogenetic Protein 7; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gluc | 2023 |
Tetrahydrocurcumin Add-On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury.
Topics: Animals; Antioxidants; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
Unilateral nephrectomized SHR/NDmcr-cp rat shows a progressive decline of glomerular filtration with tubular interstitial lesions.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Losartan; Metabolic Syndrome; Rats; Rats | 2023 |
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Ne | 2020 |
Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression.
Topics: Angiotensin II; Animals; Apoptosis; B7-1 Antigen; Class I Phosphatidylinositol 3-Kinases; Diabetic N | 2021 |
Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarker | 2018 |
Losartan improves renal function and pathology in obese ZSF-1 rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Cholesterol; Diabetes Mellitus, Experi | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus | 2018 |
A pan-NADPH Oxidase Inhibitor Ameliorates Kidney Injury in Type 1 Diabetic Rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dose-Re | 2018 |
Mast cell population in the development of diabetic nephropathy: Effects of renin angiotensin system inhibition.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2018 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Lin | 2019 |
Renoprotection Provided by Dipeptidyl Peptidase-4 Inhibitors in Combination with Angiotensin Receptor Blockers in Patients with Type 2 Diabetic Nephropathy.
Topics: Aged; Angiotensin Receptor Antagonists; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; | 2018 |
Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease.
Topics: Acetylcysteine; Actin Cytoskeleton; Angiotensin II; Animals; Calcium; Cell Adhesion; Cell Line, Tran | 2019 |
Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Models, Animal; Kidney Glomerulu | 2013 |
Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Clinical Trials as Topic; Computer Simulat | 2013 |
The protective effects of beta-casomorphin-7 against glucose -induced renal oxidative stress in vivo and vitro.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Cell Line; Diabetes | 2013 |
Is endothelial dysfunction more deleterious than podocyte injury in diabetic nephropathy?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2013 |
The authors reply.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2013 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blo | 2013 |
Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diab | 2013 |
Does losartan prevent progression of early diabetic nephropathy in American Indians with type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Losartan; Male | 2013 |
Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Humans; Losartan; Oleic Ac | 2013 |
Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cells, Cultured; Chemokine CCL2; C | 2014 |
The end of dual therapy with renin-angiotensin-aldosterone system blockade?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2013 |
Serum potassium in dual renin-angiotensin-aldosterone system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Puerarin attenuated early diabetic kidney injury through down-regulation of matrix metalloproteinase 9 in streptozotocin-induced diabetic rats.
Topics: Animals; Collagen Type IV; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, | 2014 |
Combined angiotensin inhibition in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Combined angiotensin inhibition in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Combined angiotensin inhibition in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Combined angiotensin inhibition in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Combined angiotensin inhibition in diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
[Dual blockade of the renin-angiotensin system in diabetic patients is dangerous].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropa | 2014 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Typ | 2014 |
Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Glucose; Body Weight; Desmin; Di | 2014 |
Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.
Topics: Amino Acid Transport System y+; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 1 | 2014 |
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Ir | 2014 |
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.
Topics: Albuminuria; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug | 2014 |
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
Topics: Analysis of Variance; Angiotensin II; Animals; Arachidonic Acids; Desmin; Diabetes Mellitus, Type 2; | 2014 |
Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
Topics: Aged; Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrasen | 2015 |
The protective effect of losartan on diabetic neuropathy in a diabetic rat model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Losartan; Male; Rats; Rats, Spragu | 2015 |
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
COMPARISON OF LOSARTAN AND ENALAPRIL EFFECTS ON RENAL FUNCTION IN HYPERTENSIVE ADULTS WITH CHRONIC KIDNEY DISEASE AT A KENYAN REFERRAL HOSPITAL.
Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diabetic Nephropathies; Enalapril; Female; Humans; | 2014 |
Comparison of the effects of levocetirizine and losartan on diabetic nephropathy and vascular dysfunction in streptozotocin-induced diabetic rats.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Cetirizine; Diabetes Mellitus, Experimental; Diabetic Ne | 2016 |
Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Role of O-linked N-acetylglucosamine modification in diabetic nephropathy.
Topics: Acetylglucosamine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2016 |
Inhibiting MicroRNA-503 and MicroRNA-181d with Losartan Ameliorates Diabetic Nephropathy in KKAy Mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Kidney | 2016 |
Aliskiren and dual therapy in type 2 diabetes mellitus.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; | 2008 |
Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Biopterins; Diabetes Mellitus, Expe | 2008 |
Effect of losartan on cyclooxygenase-2 expression in normal human mesangial cells and kidneys of rats with diabetic nephropathy.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Diabetic Nephropathies; Humans; Losa | 2008 |
[The effect of losartan on glomerular sclerosis in rats with diabetic nephropathy].
Topics: Animals; Collagen Type IV; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabeti | 2008 |
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropa | 2008 |
Regression of glomerular injury by losartan in experimental diabetic nephropathy.
Topics: Animals; Antihypertensive Agents; Cell Proliferation; Diabetic Nephropathies; Disease Models, Animal | 2009 |
Telmisartan is more effective than losartan in reducing proteinuria.
Topics: Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Losartan; Prote | 2009 |
Battle against the renin-angiotensin system: help from an unexpected party.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Disease Models, Animal; Di | 2009 |
Intensive diabetes management for high-risk patients: how best to deliver?
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Delivery of Health Ca | 2009 |
Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Cyto | 2009 |
Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Urea Nitrogen; Blotting, Western; Cardiomyop | 2009 |
[Economic impact of Losartan use in type 2 diabetic patients with nephropathy].
Topics: Angiotensin II Type 1 Receptor Blockers; Chile; Cost of Illness; Cost-Benefit Analysis; Diabetes Mel | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Crea | 2010 |
Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Topics: Albuminuria; Amides; Animals; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 2010 |
Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Diabetes Mel | 2010 |
Renin-Angiotensin system blockade for diabetic nephropathy prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Typ | 2010 |
Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate.
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure | 2010 |
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Diabe | 2010 |
High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB.
Topics: Angiotensin II; Cell Line; Cyclic AMP Response Element-Binding Protein; Diabetic Nephropathies; Gluc | 2011 |
The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.
Topics: Albuminuria; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 2011 |
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2010 |
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blo | 2011 |
Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.
Topics: Acute-Phase Proteins; Adult; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Fatty Ac | 2011 |
High serum potassium levels after using losartan can reflect more severe renal disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2011 |
Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2011 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failu | 2011 |
The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity.
Topics: Aldehyde Dehydrogenase; Angiotensin II Type 1 Receptor Blockers; Animals; Catalase; Diabetes Mellitu | 2012 |
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; | 2012 |
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enz | 2012 |
The therapeutic tradeoff between the adverse impacts of a lower GFR and long-term renal protection.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Have we observed the implications of the acute fall in eGFR during treatment with losartan?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Pre-renal success.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabeti | 2012 |
Therapeutic resistance to ACEI and ARB combination in macroalbuminuric diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Nephropathies; | 2012 |
The glomerular endothelium emerges as a key player in diabetic nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kidney Glomerulus; Losartan; Male | 2012 |
Optimal dose of losartan for renoprotection in diabetic nephropathy.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Diabetic Nephropathies; | 2002 |
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Topics: Angiotensin II Type 1 Receptor Blockers; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Diabe | 2002 |
Angiotensin II receptor blockade in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2003 |
Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; | 2003 |
Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diabetes | 2003 |
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea N | 2003 |
Effects of captopril and losartan on lipid peroxidation, protein oxidation and nitric oxide release in diabetic rat kidney.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2003 |
[Protective effect of angiotensin II receptor blockage on rats with experimental diabetes nephropathy in early stage].
Topics: Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2003 |
Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetes Mellitus, Experimental; Diabe | 2003 |
[Combination therapy with losartan and fosinopril for early diabetic nephropathy].
Topics: Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Fosinopril; Huma | 2003 |
Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular risk.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardio | 2003 |
[Microalbuminuria is an early marker for increased morbidity and mortality].
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biom | 2003 |
Achieved vs initial blood pressure in predicting renal outcomes.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2004 |
Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Diabetes Mellitus, | 2004 |
Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibit | 2004 |
Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood | 2004 |
[Effects of losartan on MT3-MMP and TIMP2 mRNA expressions in diabetic rat kidney].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetic Nephropathies; Kidney; Losartan; Male; Ma | 2004 |
Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Culture Techniques | 2005 |
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2005 |
Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.
Topics: Adult; Connective Tissue Growth Factor; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; G | 2005 |
[A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Clinical Tria | 2005 |
Mycophenolate mofetil ameliorates nephropathy in the obese Zucker rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2005 |
Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzamides; Diabetic Nephropathies; D | 2006 |
Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, T | 2006 |
[AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Humans; Hy | 2006 |
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Cos | 2006 |
The parathyroid hormone-related protein system and diabetic nephropathy outcome in streptozotocin-induced diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blotting, Western; | 2006 |
Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
Topics: Angiotensin II Type 1 Receptor Blockers; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabet | 2006 |
Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice.
Topics: Albuminuria; Animals; Antihypertensive Agents; Benzamides; Diabetic Nephropathies; Disease Models, A | 2007 |
CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy.
Topics: Aged; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mell | 2007 |
[Effect of integrin-linked kinase on renal tubular epithelial cell transdifferentiation in diabetic rats].
Topics: Actins; Animals; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2007 |
Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diabe | 2007 |
Overexpression of angiotensinogen increases tubular apoptosis in diabetes.
Topics: Albuminuria; Angiotensinogen; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protei | 2008 |
Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study.
Topics: Albuminuria; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Fai | 2008 |
Combination of exercise and losartan enhances renoprotective and peripheral effects in spontaneously type 2 diabetes mellitus rats with nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Diabeti | 2008 |
Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic | 2008 |
ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells.
Topics: Angiotensin II; Captopril; Cells, Cultured; Chymases; Diabetic Nephropathies; Glucose; Humans; Losar | 2008 |
Losartan in patients with renal insufficiency.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 1995 |
Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 1997 |
Pancreatitis after losartan.
Topics: Acute Disease; Adult; Antihypertensive Agents; Diabetic Nephropathies; Female; Humans; Hypertension, | 1998 |
Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy.
Topics: Adult; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents | 1999 |
The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Anions; Antihypertensive Agents; Captopril; | 1999 |
Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropa | 2000 |
Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Antihypertensive Agents; | 2000 |
Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; C | 2000 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
Drug companies should not have the final say in the design of clinical trials.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2001 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diab | 2001 |
Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy.
Topics: Animals; Anti-Bacterial Agents; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetic N | 2001 |
[Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Kidney Function | 2001 |
Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Confidence Intervals; Diabetes Mellitus, Type | 2001 |
Angiotensin-Il-receptor blockers and nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2001 |
[Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
Topics: Angiotensin II; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-U | 2001 |
[Losartan and the kidney protection. The RENAAL study].
Topics: Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2001 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2002 |
Losartan potassium (Cozaar).
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2002 |
[The RENAAL Study. Effect of losartan on diabetic nephropathy].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephr | 2002 |